Cidara Therapeutics, Inc. CDTX 深 滬
交易中 06-25 10:16:38 美东时间
221.38
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 221.38
- 總市值 69.74亿
- 52周最高 221.42
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 15.22
- 委 比 0.00%
- 總股本 3150.43万
- 歷史最高 382.60
- 量 比 0
- 振 幅 0.00%
- 歷史最低 8.00
- 每 手 1
- 風險率 65.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds AbbVie deal June 22 (Reuters) - AbbVie ABBV.N has agreed to buy biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline. The move adds to a gr
06-22 19:46
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds GSK deal June 9 (Reuters) - GSK GSK.L has agreed to buy cancer drug developer Nuvalent NUVL.O for $10.6 billion in its biggest deal in years, as the British drugmaker looks to bolster its pipeline and support long-ter
06-09 17:13
Kazia Therapeutics Appoints James Levine As CFO, Effective June 1
Mr. Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies."James has built an impressive career leading financial strategy,
06-02 19:39
Strong biopharma dealmaking market set to continue
The strong trend in pharma and biotech dealmaking, which has been ongoing for several years, should continue according to experts. Speaking at the FT US Pharma and Biotech Summit in New York, Eric Tok...
05-15 01:41
默沙东完成收购产生大额费用 上调2026年业绩指引推进收购计划
经济观察网 默沙东近期披露收购进展及最新业绩指引，已完成对Cidara Therapeutics收购，同时上调2026年营收及每股收益预期。 业务进展情况 近期...
05-06 01:06
Merck Swings To Quarterly Loss On Cidara Deal
Merck Q1 2026 results show oncology-led growth, vaccine weakness, and raised guidance after beating sales and loss estimates.
05-01 01:10
Merck Q1 earnings beat lifts shares; 2026 guidance narrowed
Merck (MRK) was up around 5% premarket on Thursday after it beat top- and bottom-line estimates for Q1 and issued a narrowed outlook for 2026. The Rahway, New Jersey–based company adjusted its guidanc...
04-30 18:59
Merck & Co Inc Stock (MRK) Moved Up by 3.18% on Apr 8: Facts Behind the Movement
• Enlicitide Phase 3 results show significant LDL reduction and safety. • Keytruda approved in EU for platinum-resistant ovarian cancer. • Merck acquired Terns Pharmaceuticals to strengthen pipeline.
04-08 18:15
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet Rewrites throughout, adds Merck's shares in paragraph 4, adds analyst comments in paragraphs 8, 13-16 March 25 (Reuters) - Merck MRK.N said on Wednesday it would buy biotech Terns Pharma TERN.O for $6.7 billion, as the drugma
03-25 18:54
